You just read:

Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology

News provided by

Debiopharm International SA

11 Oct, 2018, 11:00 BST